Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
87.48 (1y: +39%)
Market Cap 246.08 B P/E(ttm) 23.80
Enterprise Value 243.06 B P/B 3.80
JNJ- NYSE (USA)
Johnson & Johnson
  • Currently 2.5/5
Business Predictability Rank: 2.5-Star
Back Testing Results:
Average gain of all 2.5-Star stocks: 7.3% per year.
% of Stocks that are in still loss if held for 10yrs: 18%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$87.48
Switch to:
Jump to: Guru Trade | Guru Ownership | Insider Trade

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M246,082Revenue $M68,590Net Margin (%)16.1Z-Score4.9
Enterprise Value $M241,158EPS $3.8Operating Margin %23.6F-Score5
P/E(ttm))23.8Cash Flow Per Share $6.2Pre-tax Margin (%)20.5Higher ROA y-yY
Price/Book3.810-y EBITDA Growth Rate %6.2Quick Ratio2.1Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %1.5Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow11.3y-y EBITDA Growth Rate %2.3ROA % (ttm)8.9Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)16.7Less Shares Outstanding y-yN
Payout Ratio %80.0Shares Outstanding M2,795ROI % (ttm)19.3Gross Margin Increase y-yN

Gurus Latest Trades with JNJ

Please Subscribe to see portfolio changes after the end of the last quarter. Real Time Picks are included for Premium Members only! Plans start from as little as $299/year.

7-Day FREE TRIAL
Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Number of guru portfolios checked: 51.
Total Records: 15
TickerDate Action
 Impact Price Range
(Average)*down 		Current Price Change from Average Comment Current Shares
JNJ2012-12-31 Reduce-0.02%$67.97 - $72.52
($70.02)		 $ 88.4626%Reduce -33.52%327,100
JNJ2012-09-30 Reduce-0.9%$67.21 - $69.55
($68.34)		 $ 88.4629%Reduce -95.24%492,028
JNJ2012-06-30 Reduce-1.61%$61.94 - $67.65
($64.35)		 $ 88.4638%Reduce -64.39%10,333,128
JNJ2011-12-31 Reduce-0.91%$61.27 - $66.02
($63.97)		 $ 88.4638%Reduce -22.51%29,018,127
JNJ2010-09-30 Add0.17%$57.02 - $62.43
($59.49)		 $ 88.4649%Add 3.16%42,624,563
JNJ2010-06-30 Add2.21%$58 - $66.03
($62.2)		 $ 88.4642%Add 72.95%41,319,563
JNJ2010-03-31 Reduce-0.37%$62.37 - $65.36
($63.98)		 $ 88.4638%Reduce -11.95%23,891,448
JNJ2009-12-31 Reduce-0.8%$58.93 - $64.96
($62.28)		 $ 88.4642%Reduce -26.5%27,132,467
JNJ2009-06-30 Add0.51%$50.65 - $56.96
($54.11)		 $ 88.4664%Add 13.55%36,914,633
JNJ2009-03-31 Add0.5%$47.97 - $58.56
($54.2)		 $ 88.4663%Add 13.62%32,508,891
JNJ2008-12-31 Reduce-1.77%$55.39 - $62.13
($59)		 $ 88.4650%Reduce -53.67%28,611,591
JNJ2007-09-30 Add0.84%$59.37 - $65.7
($62.1)		 $ 88.4642%Add 15.92%61,607,348
JNJ2007-03-31 Add2.52%$60 - $67.37
($63.9)		 $ 88.4638%Add 97.92%48,665,600
JNJ2006-06-30 add$57.14 - $61.32
($59.1)		 $ 88.4650%24,588,800
JNJ2006-03-31 Buy $56.7 - $61.86
($58.9)		 $ 88.4650%1,970,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.
Total Records: 15

JNJ is held by these Gurus:

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Yacktman Focused Fund 2013-03-313,800,0000.144.24+22.58%
JNJ Donald Yacktman 2013-03-319,740,8750.354.1+16.02%
JNJ Yacktman Fund 2013-03-314,050,0000.143.88+15.71%
JNJ Mario Gabelli 2013-03-31463,6680.020.24+4.95%
JNJ James Barrow 2013-03-3116,479,0990.592.4+1.32%
JNJ Jean-Marie Eveillard 2013-03-311,541,9600.060.42+0.08%
JNJ Tom Gayner 2013-03-31592,8500.021.8+0.06%
JNJ Michael Price 2013-03-3145,00000.48
JNJ Meridian Funds 2013-03-317,88500.02
JNJ Prem Watsa 2013-03-315,941,6000.2118.1
JNJ Richard Perry 2013-03-31388,8970.011
JNJ Warren Buffett 2013-03-31327,1000.010.03
JNJ Tweedy Browne 2013-03-314,355,4040.169.2-0.27%
JNJ Dodge & Cox 2013-03-3139,12500-0.51%
JNJ George Soros 2013-03-312,534,0220.092.4-2.12%
JNJ PRIMECAP Management 2013-03-3113,647,3870.491.6-4.05%
JNJ Vanguard Health Care Fund 2013-03-314,268,1000.151.4-5.15%
JNJ Ruane Cunniff 2013-03-3114,76500.01-8.86%
JNJ Ray Dalio 2013-03-3176,29300.06-55.3%
JNJ Joel Greenblatt 2013-03-318,66900.04-58.46%
JNJ John Hussman 2013-03-312,65000.01-99.47%
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CULLEN JAMESDirector 2013-05-07Sell4,929$85.43.58view
LINDQUIST SUSAN LDirector 2012-12-07Sell7,600$70.0226.34view
CULLEN JAMESDirector 2012-11-12Sell13,900$69.726.92view
Caruso Dominic JCFO 2012-10-19Sell20,400$71.9522.95view
WELDON WILLIAM CChairman/CEO 2012-09-07Sell323,150$67.6630.74view
COSGROVE STEPHEN JCorporate Controller 2012-09-07Sell20,085$67.7830.51view
COLEMAN MARY SUEDirector 2012-07-19Sell7,600$69.2627.72view
DEYO RUSSELL CVP, General Counsel 2012-02-22Sell156$6536.09view
DEYO RUSSELL CVP, General Counsel 2012-02-01Sell15,000$65.7934.46view
WELDON WILLIAM CChairman/CEO 2012-02-01Sell448,085$65.9934.05view

Press Releases about JNJ:

Quarterly/Annual Reports about JNJ:

News about JNJ:

Articles On GuruFocus.com
20 Mega Caps and Their Dividend Payments and Which to Consider May 17 2013 
Why would I not sell dividend stocks even after a 1000% gain? May 15 2013 
Richard Pzena Buys 5 New Stocks May 14 2013 
6 Dividend Stocks to Beat the Wall Street Giants May 14 2013 
First Quarter 2013: Top and Bottom Performing Dividend Stocks May 07 2013 
Donald Yacktman Buys Microsoft, Coca-Cola Co, CH Robinson, Sells H&R Block, Research in Motion May 02 2013 
A Disciplined Approach to Dividend Stocks May 01 2013 
Four Attractively Priced Dividend Stocks Boosting Distributions Apr 29 2013 
Where is the Larger Bubble: the S&P 500 Index or U.S. Treasuries? Apr 26 2013 
Many of My Dividend Growth Stocks Have Become Overvalued, What Do I Do Now? Apr 25 2013 

More From Our Partners
Gilead's Sofosbuvir under European Review - Analyst Blog May 22 2013 - ZACKS

Add Notes, Comments or Ask Questions

Comments

No comment yet
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial
FEEDBACK